ESR's Meningococcal Staff at Great Risk - Chiron
ESR's Meningococcal Staff at Great
Ron Law & Barbara Sumner Burstyn
"It is somewhat puzzling that the ESR has concluded that Chiron's researcher working at the ESR was not at increased risk from the disease, yet ESR staff have a 500 times greater risk of contracting meningococcal disease than persons of a similar age, according to Chiron's Clinical Trial Application V60P4, " say risk & policy analyst, Ron Law, and writer/researcher Barbara Sumner Burstyn.
It would seem that either the recent ESR report of low occupational risk is flawed, or Chiron grossly ramped up the risk to ESR staff to justify a study involving the vaccination of ESR staff with the MeNZB(tm) vaccine.
Given that Chiron's Principal Researcher was also the Ministry of Health's Principal Meningococcal Advisor, and was also on the Minister' of Health's expert MAAC committees that recommended approval of the MeNZB(tm) vaccine, we are at a loss to explain this apparent contradiction.
This in itself raises another question: If ESR laboratory staff were vaccinated with the MeNZB(tm) vaccine in clinical trial V60P4, why has the public been told that they were not vaccinated?
This is further evidence of the need for a formal independent inquiry to unravel the truth surrounding meningococcal disease in New Zealand and the MeNZB(tm) vaccine.